Discover and read the best of Twitter Threads about #PCSK9i
Most recents (5)
1a) Welcome to a live-tweeted, #accredited #tweetorial from @nationallipid #NLA23 in #Atlanta on advances in #hyperlipidemia management #LLT. Our expert returning faculty is Pam R. Taub, MD @PamTaubMD #cardiologist from @UCSDHealth 
1b) Dr. Taub is a clinician/scientist and is a frequent contributor to our #accredited programs. She is the founding director of the Step Family Foundation Cardiac Rehabilitation and Wellness Center at #UCSD.
#FOAMed #cardiotwitter @MedTweetorials #MedEd #lipids
#FOAMed #cardiotwitter @MedTweetorials #MedEd #lipids
2) This program is supported by an educational grant from Esperion Therapeutics & is intended for #HCPs. Statement of accreditation & faculty disclosures at cardiometabolic-ce.com/disclosures/. Earn 0.75 hr 🆓CE/#CME by following this 🧵!
9) Many risk factors modulate the propensity of LDL-C to traverse the endothelium and enter the arterial intima. See 🔓academic.oup.com/eurheartj/arti….
10) It now appears that the passage of #LDL into the #intima is not a merely passive process whereby the concentration in blood & the permeability of the endothelium determine LDL accumulation.
11) It’s #Transcytosis (an active process), through a vesicular pathway involving #caveolae, scavenger receptors (#SRB1) and activin like receptor kinase 1 (#ALK1). Hence for a given blood level of LDL-C the amount of atherosclerosis is variable.
1) Welcome to @cardiomet_CE's new series on #lipid management! This is a 10-#tweetorial program, all #accredited, that will cover it all. Our first expert author is Paul Thompson MD @PaulDThompsonMD, esteemed #cardiologist from @hartfordhosp @UConn Med & now @MGHHeartHealth !
2) This #tweetorial, accredited for #CME/CE and intended for #physicians #physicianassociates #nurses #nursepractitioners #pharmacists is supported by an educational grant from Esperion Therapeutics. See faculty disclosures at cardiometabolic-ce.com/disclosures/.
3) @PaulDThompsonMD took on education re mechanisms & use of ezetimibe & bempedoic acid. He proposes a case: 45 ♂️ w/history of inferior wall #MI treated with primary angioplasty.
1) Welcome to @cardiomet_CE's series on #lipid management! This is a 10-#tweetorial program, all #accredited, that will cover IT ALL. The expert author for this module is Robert Giugliano MD @ @rgiugliano, renowned #cardiologist from @BrighamWomens & @harvardmed !
2) This #tweetorial, accredited for #CME/CE and intended for #physicians #physicianassociates #nurses #nursepractitioners #pharmacists is supported by an educational grant from Esperion Therapeutics. See faculty disclosures at cardiometabolic-ce.com/disclosures/.
3) @rgiugliano is going to discuss care of patients taking #statins who still have residual atherosclerotic cardiovascular disease #ASCVD risk.
#CVLipids #CardioTwitter #PriorAuthDenial
A thread for education, dissipation of annoyance, and showcase for silliness of insurance prior authorization. @UHC @askUHC @UHC_EH @myUHC 1/
A thread for education, dissipation of annoyance, and showcase for silliness of insurance prior authorization. @UHC @askUHC @UHC_EH @myUHC 1/
#PCSK9i
1.Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL Receptor (LDLR)
2.LDLR, protein that brings LDL into the liver cell to be broken down
3.PCSK9=overmanaging boss who fires you despite a job well done
#CVLipids #CardioTwitter #PriorAuthDenial 2/
1.Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL Receptor (LDLR)
2.LDLR, protein that brings LDL into the liver cell to be broken down
3.PCSK9=overmanaging boss who fires you despite a job well done
#CVLipids #CardioTwitter #PriorAuthDenial 2/
Source of graphic above: pharmaceutical-journal.com/article/featur… Excellent read by the way :) #CVLipids #CardioTwitter #PriorAuthDenial 3/
